Charlie Dawson

Authored Items
The Value of Some Cancer Drugs Changes Substantially After Their Approval
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Value-Based Care
Clinical Decision Support Helps Compliance with Evidence-Based Pathways
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Value-Based Care
Cemiplimab Cost-Effective for Advanced Cutaneous Squamous-Cell Carcinoma
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Value-Based Care
Germline Analysis Proves Valuable in Selecting Targetable Treatments for Patients with Advanced Cancer
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Value-Based Care
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Multiple Myeloma
Bortezomib, Lenalidomide, and Dexamethasone Remains Standard of Care for Initial Treatment of Patients with Newly Diagnosed Multiple Myeloma
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Multiple Myeloma
Long-Term Data Support Use of Acalabrutinib in Patients with Treatment-Naïve CLL
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Leukemia
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Colorectal Cancer
Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors
Charlie Dawson
TOP - September 2020 Vol 13, No 5 in Emerging Therapies
Last modified: August 17, 2020